Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.48 |
| ▸ | RHOC | P08134 | 1/20 | 0.47 |
| ▸ | RHOA | P61586 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358527 | 0.92 | HDAC3 (0.58) | CSF1RHDAC3HDAC8HDAC6MAPK14 | |
| SCHEMBL12465329 | 0.88 | P2RY14 (0.53) | CSF1RHDAC3HDAC8HDAC6MAPK14 | |
| SCHEMBL17413291 | 0.86 | CSF1R (0.53) | CSF1RHDAC3HDAC8HDAC6MAPK14 | |
| SCHEMBL22025295 | 0.85 | PTGS1 (0.64) | KITBTKPTGS1MEN1RAB9A | |
| SCHEMBL4421970 | 0.85 | CSF1R (0.55) | CSF1RHDAC3HDAC8HDAC6MAPK14 | |
| SCHEMBL4437612 | 0.85 | CSF1R (0.52) | CSF1RHDAC3HDAC8HDAC6MAPK14 | |
| SCHEMBL4973741 | 0.85 | BRAF (0.51) | KDRBRAF | |
| SCHEMBL12464982 | 0.84 | HDAC3 (0.47) | CSF1RHDAC3HDAC8HDAC6MAPK14 | |
| SCHEMBL29921468 | 0.84 | CSF1R (0.51) | CSF1RHDAC3HDAC8HDAC6MAPK14 | |
| SCHEMBL29071507 | 0.84 | CSF1R (0.51) | CSF1RHDAC3HDAC8HDAC6MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658290-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-15 | — | — | EP | claimed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | claimed |
| JP-2007504159-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | claimed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | claimed |
| EP-1658290-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-15 | — | — | EP | disclosed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | LCK, FYN, BMX | CSF1R 915/4885HDAC3 1602/4885HDAC8 1854/4885 |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | CSF1R 818/4885HDAC3 4366/4885HDAC8 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.